Elevated CD86 mRNA expression has recently been demonstrated as a potential prognostic biomarker for glioblastoma [30], and significantly enhanced CD80 and CD86 mRNA expression was detected in peripheral blood samples of CRC patients [31]. This evidence concerns the gene CD86 and colorectal carcinoma.